Guidance and quality standards Awaiting development

Skip to filters Skip to results

Showing 301 to 307 of 307

Type: GuidanceRemove Type: Guidance filter
Type: Quality standardRemove Type: Quality standard filter
Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter
Guidance programme: Interventional procedures guidanceRemove Guidance programme: Interventional procedures guidance filter
Guidance programme: Diagnostics guidanceRemove Guidance programme: Diagnostics guidance filter
Guidance programme: Highly specialised technologies guidanceRemove Guidance programme: Highly specialised technologies guidance filter
Guidance programme: Antimicrobial prescribing guidelinesRemove Guidance programme: Antimicrobial prescribing guidelines filter
Guidance programme: Cancer service guidelinesRemove Guidance programme: Cancer service guidelines filter
Guidance programme: Clinical guidelinesRemove Guidance programme: Clinical guidelines filter
Guidance programme: Medicines practice guidelinesRemove Guidance programme: Medicines practice guidelines filter
Guidance programme: Public health guidelinesRemove Guidance programme: Public health guidelines filter
Guidance programme: Safe staffing guidelinesRemove Guidance programme: Safe staffing guidelines filter

Guidance and quality standards awaiting development
Title	Type
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765	Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable TS ID 10477	Technology appraisal guidance
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments TS ID 11952	Technology appraisal guidance
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments [ID6416]	Technology appraisal guidance
Zavegepant for treating acute migraine TSID 11998	Technology appraisal guidance
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer TSID 12040	Technology appraisal guidance
Zuranolone for treating severe postnatal depression ID6431	Technology appraisal guidance

Results per page

10
25
50
All